Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: The pediatric oncology group experience - A pediatric oncology group study

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2007-2017

  Katzenstein, Howard M ^a   Bowman, Laura C ^a   Brodeur, Garrett M ^a   Thorner, Paul S ^a   Joshi, Vijay V ^a   Smith, E Ide ^a   Look, A Thomas ^a   Rowe, Susan T ^a   Nash, Michael B ^a   Holbrook, Tate ^a   Alvarado, Carlos ^a   Rao, P V ^a   Castleberry, Robert P ^a   Cohn, Susan L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; ONCOPROTEIN; TENIPOSIDE;

ARTICLE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHILDHOOD CANCER; CLINICAL PROTOCOL; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; ONCOGENE C MYB; ONCOGENE C MYC; ORAL DRUG ADMINISTRATION; PLOIDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031749828     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2007     Document Type: Article

References (48)

1. Evans AE, Gerson J, Schnaufer L: Spontaneous regression of neuroblastoma. Natl Cancer Inst Monogr 44:49-54, 1976
2. Evans AE, D'Angio GJ, Randolph J: A proposed staging for children with neuroblastoma. Children's Cancer Study Group A. Cancer 27:374-378, 1971
3. Nitschke R, Smith EI, Shochat S, et al: Localized neuroblastoma treated by surgery: A Pediatric Oncology Group study. J Clin Oncol 6:1271-1279, 1988
4. Brodeur GM, Seeger RC, Barrett A, et al: International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6:1874-1881, 1988
5. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
6. D'Angio GJ, Evans AE, Koop CE: Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1:1046-1049, 1971
7. Stokes SH, Thomas PR, Perez CA, et al: Stage IV-S neuroblastoma. Results with definitive therapy. Cancer 53:2083-2086, 1984
8. Evans AE, Chatten J, D'Angio GJ, et al: A review of 17 IV-S neuroblastoma patients at the Children's Hospital of Philadelphia. Cancer 45:833-839, 1980
9. Jereb B, Bretsky SS, Vogel R, et al: Age and prognosis in neuroblastoma. Review of 112 patients younger than 2 years. Am J Pediatr Hematol Oncol 6:233-243, 1984
10. Evans AE, Baum E, Chard R: Do infants with stage IV-S neuroblastoma need treatment? Arch Dis Child 56:271-274, 1981
11. Haas D, Ablin AR, Miller C, et al: Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer 62:818-825, 1988
12. Schwartz AD, Dadash-Zadeh M, Lee H, et al: Spontaneous regression of disseminated neuroblastoma. J Pediatr 85:760-763, 1974
13. Mancini AF, Rosito P, Vitelli A, et al: IV-S neuroblastoma: A cooperative study of 30 children. Med Pediatr Oncol 12:155-161, 1984
14. Stephenson SR, Cook BA, Mease AD, et al: The prognostic significance of age and pattern of metastases in stage IV-S neuroblastoma. Cancer 58:372-375, 1986
15. Nickerson HJ, Nesbit ME, Grosfeld JL, et al: Comparison of stage IV and IV-S neuroblastoma in the first year of life. Med Pediatr Oncol 13:261-268, 1985
16. van Noesel MM, Hahlen K, Hakvoort-Cammel FGAJ, et al: Neuroblastoma 4S: A heterogeneous disease with variable risk factors and treatment strategies. Cancer 80:834-843, 1997
17. Brodeur GM, Seeger RC, Schwab M, et al: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121-1124, 1984
18. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111-1116, 1985
19. Look AT, Hayes FA, Nitschke R, et al: Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311:231-235, 1984
20. Look AT, Hayes FA, Shuster JJ, et al: Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 9:581-591, 1991
21. Cohn SL, Rademaker AW, Salwen HR, et al: Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma. Am J Pathol 136:1043-1052, 1990
22. Taylor SR, Blatt J, Costantino JP, et al: Row cytometric DNA analysis of neuroblastoma and ganglioneuroma. A 10-year retrospective study. Cancer 62:749-754, 1988
23. Bourhis J, DeVathaire F, Wilson GD, et al: Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res 51:33-36, 1991
24. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al: Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328:847-854, 1993
25. Kogner P, Barbany G, Dominici C, et al: Coexpression of messenger RNA for TRK proto-oncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res 53:2044-2050, 1993
26. Borrello MG, Bongarzone I, Pierotti MA, et al: TRK and RET proto-oncogene expression in human neuroblastoma specimens: High-frequency of TRK expression in non-advanced stages. Intl J Cancer 54:540-545, 1993
27. Suzuki T, Bogenmann E, Shimada H, et al: Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 85:337-384, 1993
28. Hayashi Y, Kanda N, Inaba T, et al: Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1. Cancer 63:126-132, 1989
29. Caron H, van Sluis P, de Kraker J, et al: Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 334:225-230, 1996
30. Maris JM, White PS, Beltinger CP, et al: Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 55:4664-4669, 1995
31. Bowman LC, Castleberry RP, Cantor A, et al: Genetic staging of unresectable or metastatic neuroblastoma in infants: A Pediatric Oncology Group study. J Natl Cancer Inst 89:373-380, 1997
32. Nakagawara A, Sasazuki T, Akiyama H, et al: N-myc oncogene and stage IV-S neuroblastoma. Preliminary observations on 10 cases. Cancer 65:1960-1967, 1990
33. Tonini GP, Boni L, Pession A, et al: MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: The Italian Experience with 295 children. J Clin Oncol 15:85-93, 1997
34. Cohn SL, Herst CV, Maurer HS, et al: N-myc amplification in an infant with stage IVS neuroblastoma. J Clin Oncol 5:1441-1444, 1987
35. Bourhis J, Dominici C, McDowell H, et al: N-myc genomic content and DNA ploidy in stage IVS neuroblastoma. J Clin Oncol 9:1371-1375, 1991
36. Shapiro DN, Valentine MB, Rowe ST, et al: Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma. Am J Pathol 142:1339-1346, 1993
37. Shimada H, Chatten J, Newton WA Jr, et al: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405-416, 1984
38. Garvin J Jr, Bendit I, Nisen PD: N-myc oncogene expression and amplification in metastatic lesions of stage IV-S neuroblastoma. Cancer 65:2572-2575, 1990
39. Wilson PC, Coppes MJ, Solh H, et al: Neuroblastoma stage IV-S: A heterogeneous disease. Med Pediatr Oncol 19:467-472, 1991
40. Hachitanda Y, Hata J: Stage IVS neuroblastoma: A clinical, histological, and biological analysis of 45 cases. Hum Pathol 27:1135-1138, 1996
41. Cohn SL, Look AT, Joshi VV, et al: Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: A Pediatric Oncology Group study. Cancer Res 55:721-726, 1995
42. Savilo E, Harnish DG, Desa D, et al: Comparison of the prognostic significance of the Shimada classification and N-myc copy number in neuroblastoma: A prospective study. Int J Oncol 8:343-347, 1996
43. Shimada H, Stram DO, Chatten J, et al: Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 87:1470-1476, 1995
44. Gehring M, Berthold F, Edler L, et al: The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res 55:5366-5369, 1995
45. Norris MD, Bordow SB, Marshall GM, et al: Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334:231-238, 1996
46. McWilliams NB: IV-S neuroblastoma: Treatment controversy revisited. Med Pediatr Oncol 14:41-44, 1986
47. Martinez DA, King DR, Ginn-Pease ME, et al: Resection of the primary tumor is appropriate for children with stage IV-S neuroblastoma: An analysis of 37 patients. J Pediatr Surg 27:1016-1020, 1992
48. Guglielmi M, De Bernardi B, Rizzo A, et al: Resection of primary tumor at diagnosis in stage IV-S neuroblastoma: Does it affect the clinical course? J Clin Oncol 14:1537-1544, 1996